950160.KQ
Kolon TissueGene, Inc.
KOE · Healthcare · Biotechnology · US
KRW 16,910.00
−5.53%Year over year
Reported trailing growth
- Revenue
- -13.5%
- EBITDA
- -38.3%
- EBIT
- -4.0%
- EPS
- -98.4%
- Free cash flow
- +52.2%
- Operating cash flow
- +26.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -18.3%
- EBITDA
- +34.7%
- EBIT
- -1.4%
- Net income
- —
- EPS
- —
- Free cash flow
- +74.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026